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The objective of this study was to present a systematic review of the central nervous system (CNS) types of
anomalies and to consider the possibility to include CNS anomalies in Incontinentia pigmenti (IP) criteria. The
analyzed literature data from 1,393 IP cases were from the period 1993–2012. CNS anomalies were diagnosed for
30.44% of the investigated IP patients. The total number of CNS types of anomalies per patient was 1.62. In the
present study there was no significantly higher number of anomalies per patient in females than males. The most
frequent CNS types of anomalies were seizures, motor impairment, mental retardation, and microcephaly. The most
frequently registered CNS lesions found using brain imaging methods were brain infarcts or necrosis, brain
atrophies, and corpus callosum lesions. IKBKG exon 4–10 deletion was present in 86.00% of genetically confirmed IP
patients. The frequency of CNS anomalies, similar to the frequency of retinal anomalies in IP patients, concurrent
with their severity, supports their recognition in the list of IP minor criteria.
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Incontinentia pigmenti (IP [MIM 308300], Bloch-
Sulzberger syndrome, ORPHA464) is a rare X-linked
genodermatosis with estimated prevalence 0.2/100,000
[1] in which changes of skin and skin appendages are
usually combined with anomalies of other organs: teeth,
eyes, and central nervous system (CNS) [2]. IP appears
almost exclusively in females and is usually lethal in
males [3,4]. Mutations of the IKBKG (inhibitor of kappa
B kinase gamma, previously NEMO) gene, localized on
the X-chromosome, locus Xq28, are responsible for IP
[5]. IKBKG gene product activates NF-κB (nuclear
factor-kappa B), transcription factor that regulates the
expression of hundreds of genes in almost all cells [6-9].
The highest expresion level of IKBKG was noted in CNS
[10]. IP results from enhanced apoptosis due to muta-
tions in the IKBKG gene [3]. The phenotypic variability
of IKBKG mutation expression [5,11] is likely to be the
result of skewed X-chromosome inactivation and due to
the pleiotropic role of the IKBKG gene product
[10,12,13]. Proposed criteria for IP were set by Landy* Correspondence: dtrpinac@eunet.rs
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reproduction in any medium, provided the orand Donnai [3] and have been in routine practice since
then. CNS anomalies usually occur from the neonatal
through the early infantile period and represent the most
important threat to the normal life span of patients with
IP [4,14]. CNS anomalies in IP include seizures, mental
retardation, hemiplegia, hemiparesis, spasticity, micro-
cephaly, and cerebellar ataxia [3,15].
Since 1906, when IP was described for the first time
[16], there have been numerous reports of CNS anomal-
ies in IP patients. We made a systematic review to ob-
tain an overview of relevant aspects of CNS findings in
IP. The systematic review covered data in the available
literature of IP cases published between 1993, when
Landy and Donnai [3] proposed IP criteria, and 2012.
The objective of the present study was to determine
whether there were any differences between the number
and type of anomalies according to sex, to investigate
the severity of the anomalies, to discuss possibilities for
their correction, and to consider the possibility to in-
clude CNS anomalies in IP criteria in the context of
their frequency and severity. The discovery of IKBKG as
the IP causative gene [5] enabled molecular genetic con-
firmation of IP. The correlation of genetic data and the
clinical phenotype, with the main focus on CNS findings,
was investigated. Additional data concerning IPtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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presented (see Additional file 1: Central nervous system
anomalies in incontinentia pigmenti in the period 1906-
1993).
Methods
Available literature data concerning IP cases published
between 1993 and 2012 were analyzed. A literature
search was conducted using following databases:
PubMed (http://www.ncbi.nlm.nih.gov/pubmed), Na-
tional Library of Serbia - KoBSON – Serbian Library
Consortium for Coordinated Acquisition of Literature
(http://kobson.nb.rs/kobson.82.html/), Google Scholar
(http://scholar.google.com/schhp?hl=en), and references
cited in the articles found. The following search algo-
rithms were used: “Incontinentia pigmenti” and “Bloch-
Sulzberger syndrome.” All references with the relevant
data independent of article type in English and other
languages were included in the study. Clinical data and
diagnostic information were collected from abstract or
full text of the articles searched for in the databases.
Only cases of IP with a confirmed diagnosis, the pro-
bands as well as their IP positive relatives ascertained
after the diagnosis in the proband, were included.
Detailed clinical, brain imaging, and laboratory data
needed to be described for case reports. Exact IP diag-
nostic criteria had to be included for research reports.
For systematic review 318 references from the literature
with acceptable data for this study were found. Analyzed
studies covered the pan-ethnic IP patients’ populations
in Europe, Asia, Africa, Australia, North America, and
South America. These references are listed separately
(see Additional file 2: Additional references published in
the period of 1993-2012). The validity of the analyzed
articles was taken for granted and was not assessed.
Whenever possible we excluded multiplications of data,
such as patients described in more than one reference.
In this analysis, the following were considered as CNS
anomalies: all types of seizures, motor impairment, men-
tal retardation, microcephaly, and anomalies registered
in small number or unspecified anomalies. The following
were classified as motor impairment: cerebral palsy,
hemiplegia, hemiparesis, spasticity, and ataxia. The num-
ber of CNS anomaly types per patient by sex was
counted. Quite often, an individual patient had more
than one type of CNS anomaly.
Anomalies that produced mild and temporary pro-
blems in patients were classified as mild, whereas all
anomalies that significantly and permanently affected
patients’ health and quality of life were classified as
severe.
To collect data about CNS morphological changes in
IP patients with neurological symptomatology we ana-
lyzed articles in which brain imaging methods, usuallyMRI (magnetic resonance imaging) and CT (computed
tomography), were used. The lesions registered using
brain imaging methods were classified as brain infarcts/
necrosis, brain atrophies, dilated brain ventricles, brain
cystic lesions, corpus callosum lesions (including hypo-
plasia and agenesis), and rarely diagnosed or unspecified
CNS lesions. To determine the effect of different IKBKG
mutations on the clinical phenotype, the CNS anomalies
of IP patients with a proven IKBKG mutation were ana-
lyzed separately. In addition, the relationship between
the occurrence of CNS anomalies and ocular and dental
anomalies as the most frequent accompanying disorders
in IP patients was investigated. The collected data were
mainly frequencies that were presented in tables. All cal-
culations were performed in Microsoft Office Excel™
2003.
Results
As outlined above, in the present study the literature
data concerning IP patients with associated CNS anom-
alies were investigated. The results are presented in
tables. The total number of IP patients found in the lit-
erature during the period 1993–2012 was 1,393 (92.96%
females, 6.60% males, and 0.43% without adequate data
regarding sex in literature) (Table 1). Among 795 neuro-
logically investigated IP patients, CNS anomalies were
observed in 30.44% of them. The total number of CNS
types of anomalies per patient was 1.62. The most fre-
quent types of CNS anomalies were seizures, motor im-
pairment, and mental retardation, which comprise
41.98%, 25.70%, and 20.36%, respectively, of all observed
types of CNS anomalies. Microcephaly was found in
4.07% of patients, and 7.89% of anomalies were rare or
unclassified. Most (61.98%) of IP patients with CNS
findings suffered from severe CNS anomalies. The
results of the present statistical analysis of data by sex
showed that there was no significant difference in the
number of types of CNS anomalies per patient (χ2=0.42;
df=1; p=0.71>0.05), in the distribution of patients with
mild and severe anomalies (χ2=0.00006; p=0.99>0.05),
and in the distribution of CNS anomalies (χ2=0.21; df=2;
p=0.90>0.05). The Chi-square test was not used to test
distribution by sex of microcephaly and types of CNS
anomalies found in small numbers or unspecified be-
cause the expected frequency for male IP patients for
these CNS anomalies (even when grouped together) was
less than five [17].
For total of 139 IP patients (6 of them males) we had
sufficient data to analyze the age of occurrence of first
neurological manifestation. The first neurological mani-
festations occurred in the first week in 58.3%, in the first
month of life in 66.9%, and in the first year in 87.8% IP
patients. In all analyzed intervals was registered higher
number of severe compared to mild anomalies.
Table 1 The main findings of IP patients and CNS anomalies by sex for the period 1993-2012



































Total* 1,393 795 242 393 1.62 165 80 101 16 31 92 150
Female 1,295 719 221 361 1.63 152 73 94 15 27 84 137
Male 92 76 21 32 1.52 13 7 7 1 4 8 13
* For six patients, data concerning sex were not available in the literature.
** The task of counting and identifying anomalies in some references was challenging because there were only lists of observed anomalies with no exact numbers. These lists included frequent types of CNS anomalies
such as seizures, motor impairment, mental retardation, and microcephaly. These anomalies were classified as unspecified anomalies together with different anomalies presented in small numbers. In this investigation,
of 31 registered rare or unspecified CNS anomalies, 15 were unspecified but frequent types of CNS anomalies (seizures, motor impairment, mental retardation, and microcephaly). Because of these difficulties, the exact
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using brain imaging methods (Table 2) were brain
infarcts or necrosis, brain atrophies, and corpus callo-
sum lesions (24.55%, 17.36%, and 13.17% respectively),
whereas rarely diagnosed or unspecified CNS lesions
represented 30.54%.
IKBKG mutations were confirmed for 50 IP patients
with CNS anomalies (Table 3). They represent 11.11% of
the total number of registered IP patients with CNS
anomalies. Three of them were males, and all had
IKBKG exon 4–10 deletion. In IP patients positive for
IKBKG mutations (Table 4) 86.00% were found to have
IKBKG exon 4–10 deletion whereas 14.00% had other
than IKBKG exon 4–10 mutation listed in Table 5. The
total number of CNS types of anomalies per patient was
1.54 in IP patients with genetically confirmed IP and
1.62 in patients without genetically confirmed IP. The
total number of CNS anomalies per patient was 1.42 in
IP patients with a common exon 4–10 deletion and 2.28
in IP patients with other types of IKBKG mutations. The
result of the present statistical analysis according to gen-
etical confirmation showed that there was no significant
difference in the number of CNS anomaly types per pa-
tient (χ2=0.17; df=1; p=0.68>0.05) or in the distribution
of seizures, mental retardation, and motor impairment
(χ2=2.16; df=2; p=0.54>0.05). Severe CNS types of anom-
alies were found in 63.22% of IP patients with CNS
anomalies without genetically confirmed IP and in
54.00% of IP patients with CNS types of anomalies that
were positively genetically tested for the IKBKG muta-
tion, but the difference was not significant (χ2=1.35;
df=1; p=0.24>0.05).
In this analysis of literature data, of 242 IP patients with
CNS anomalies, 186 were ophthalmologically investigated,
and 101 (54.30%) of them had associated ocular anomal-
ies. A total of 115 IP patients were investigated stomatolo-
gically, and 80 (69.56%) of them had dental and/or oral
anomalies. A total of 41 (36.93%) IP patients had CNS,
ocular, and dental and/or oral anomalies simultaneously.
Discussion
The results of this investigation presented the distribu-
tion by sex similar to the results of other studies [2,15].Table 2 Distribution of brain imaging lesion findings by sex i
Sex Total number









Total 89 167 29 41
Female 84 161 27 39
Male 5 6 2 2The percentage of IP patients with CNS anomalies was
similar to the results of Carney [15] and Hadj-Rabia
et al. [20], 30.5% and 32%, respectively. However, Fusco
et al. [12] identified 13% and Kim et al. [21] identified
35% IP patients with CNS anomalies. These discrepan-
cies could be explained by the differences in the IP
patients’ cohort. The results of present statistical analysis
of data by sex showed that there was no significant dif-
ference in the number of CNS anomaly types per patient
or in the distribution of seizures, mental retardation,
and motor impairment.
Besides limitations such as heterogeneity, different
definitions, and criteria for their diagnosis, frequencies
of seizures, motor impairment, mental retardation, and
microcephaly were generally higher than in the corre-
sponding general population. For example, according to
Eurocat Prevalence Data Tables [22] microcephaly for
live births for the 2005–2009 period was 1.67 per 10,000
births. In the general population the prevalence of epi-
lepsy was 0.005-0.01% [23], and the prevalence of mental
retardation was 1-3% [24].
In the present study there was no significantly higher
number of anomalies per patient in females than males.
Fusco et al. [12,25] found higher values, 2.25 CNS
anomaly types per patient in females and 2.40 in males,
whereas Kim et al. [21] found only one CNS anomaly
type per patient. Fusco et al. [12,25] found 13.55% in fe-
male and 35.71% in male IP patients with CNS anomal-
ies. These differences in findings very likely originate
from different sample sizes, and, because of the larger
sample size, the results of the present study were more
reliable.
Because pathoanatomical findings in IP patients were
very rare [26-28], brain imaging methods gave the ma-
jority of data concerning the morphological aspects of
CNS lesions [29]. The most frequently registered CNS
lesions with the brain imaging method were brain
infarcts or necrosis, brain atrophy, and corpus callosum
lesions.
Besides the fact that IP results from enhanced apop-
tosis due to mutations in the IKBKG gene [3,4,10], patho-
genesis of CNS lesions in IP is still controversial issue.
The CNS lesions may share a common pathophysiologicn IP patients with CNS lesions for the period 1993-2012
Distribution of brain imaging
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Number of Distribution of CNS anomaly types in numbers Distribution of IP patients
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Total 205 329 1.60 141 66 82 12 28 80 125
IP patients without
genetical confirmation
155 252 1.62 111 55 69 9 8 57 98
IP patients with
genetical confirmation




















Table 4 Number of IP patients with CNS anomalies and confirmed IKBKG mutations, CNS anomaly types, and its distribution according to type of IKBKG
mutation for the 2001–2012 period
Type of IKBKG
mutation


























50* 77 1.54 28 30 11 13 3 20
IKBKG exon 4–
10 deletion




7** 16 2.28 1 2 2 4 2 6
* Three of them were males.




















Table 5 List of IKBKG mutations except IKBKG exon 4–10 deletion for the 2001–2012 period in IP patients with CNS
anomalies
Reference Type of IKBKG mutation Type of anomalies Diagnosis
Rola et al. 2004 [18] Nonsense mutation c.397C>T
(p.Gln133Term)
Motor impairment Incontinentia pigmenti




1150C!T 1 unspecified* frequent anomaly Incontinentia pigmenti
1077–1078delC 3 unspecified* frequent
anomalies
Incontinentia pigmenti
1115–1116delT 1 unspecified* frequent anomaly Incontinentia pigmenti




Motor impairment Incontinentia pigmenti, transient
immunodeficiency








All IP patients were females.
* Unspecified frequent anomalies: seizures, motor impairment, mental retardation and microcephaly.
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inas of IP patients [30-32]. However, other brain imaging
and pathoanatomical studies fail to show a relationship
between brain abnormalities and vascular patterns
[14,26]. Brain infarcts found in IP patients [30-32] sup-
ported the hypothesis of vascular pathogenesis of CNS
lesions in IP, whereas findings of brain atrophy [11,20],
corpus callosum lesions [14,20], disorder of myelination
[27,33] and lack of relationship between brain abnormal-
ities and vascular patterns [14,26] supported the hypoth-
esis of disorder of the NF-κB metabolic pathway in
neurons and glia cells as a pathogenetic mechanism.
CNS lesions in IP can result from the same pathogen-
esis as skin [4], by inducing apoptosis of IKBKG mutated
cells because the CNS, such as the skin, is of ectodermal
origin. The evolution of the lesions can be interpreted as
representing the death of cells that have the IKBKG
mutation-bearing X-chromosome as the active one and
their replacement by cells in which the normal X-
chromosome is active [34]. Considering the similarities
between IP retinopathy and retinopathies of prematurity
[10,35] and in diabetes [35], the fact that apoptosis in
the diabetic rat retina occurred before changes in micro-
circulation [35] indicates that a similar process may
occur in the retina and the CNS of IP patients. One
must bear in mind the fact that apoptosis is a process
defined by manifesting specific morphological and mo-
lecular features, visible only in histological sections
under microscope [36,37], not visible directly and clinic-
ally in patient. It is possible that in the CNS, as in the
retina, apoptotic changes precede vascular changes, butthe first clinically noticeable signs in IP patients are vas-
cular changes. In the experimental model of retinopathy
of prematurity occurred apoptosis of endothelial cells in
the developing retina, leading to vaso-obliteration fol-
lowed by proliferative retinopathy [38]. It is possible to
speculate that, besides parenchymal cells, apoptosis
occurs in blood vessel walls’ cells of affected organs. For
the time being there is no evidence for such a hypothesis.
Besides apoptosis, some other processes occurred in
IKBKG mutation affected tissue. IKBKG mutation leads
to expression of eotaxin, chemokine chemotactic for
eosinophils [39] responsible for eosinophil infiltration
[40]. Eotaxin is abnormally expressed in epidermis
affected by IKBKG mutation and in vascular endothelial
cells, findings which correlate with eosinophil infiltration
in the skin [40]. Perivascular eosinophil deposition has
been observed along with endothelial cell degeneration
within retinal blood vessels [41]. It was proposed that
apoptotic keratinocytes act leading to inflammatory
responses inducing synthesis and release of different
chemokines including eotaxin and sequent eosinophil
infiltration [40]. There is also proposal that vascular
endothelial growth factor (VEGF) receptor is involved in
the vascular changes in IP [10,26]. As NF-κB is involved
in the transduction system of the messages received by
the VEGF receptor, disorder of the transmission of this
message in IP might influence cerebral microvasculariza-
tion [10,26].
Taking into account all the facts presented, identical
pathophysiological mechanisms of IP development with
apoptosis as a key event occur in all affected tissues,
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appear secondary to apoptosis.
A group of 50 IP patients from the literature with
CNS anomalies that were positive tested for IKBKG
mutations was independently analyzed. The percentage
of IP patients with common exon 4–10 deletion is simi-
lar to the results (80%) of Smahi and The International
Incontinentia Pigmenti Consortium [5]. Although the
number of CNS anomaly types was higher for common
IKBKG exon 4–10 deletion, the difference was not sig-
nificant. Fusco et al. [25] found a similar distribution:
2.00 CNS anomaly types per IP patient with IKBKG
exon 4–10 deletion and 2.50 CNS anomaly types per IP
patient with other than IKBKG exon 4–10 deletion.
However, because of the low number of documented
patients with other than IKBKG exon 4–10 mutations
this can be also the result of a statistical bias. The correl-
ation between type of IKBKG mutation and IP pheno-
type expression was not found up to date.
We investigated the relationship of the simultaneous
occurrence of the most frequent IP extracutaneous
anomalies: CNS, ocular, and dental and/or oral anomal-
ies. Based on literature data of a selected series of 29 IP
patients with MRI confirmed CNS anomalies, from
which 20 (68.96%) had associated ocular anomalies, it
was speculated that ocular anomalies increase the
chance of CNS anomalies in IP patients [30]. However,
Fusco et al. [12] in a series of 59 genetically confirmed
IP females found eight patients with CNS anomalies,
only four of whom had associated ocular anomalies. In
the Hadj-Rabia et al. [20] study only three of 13 IP
patients with CNS anomalies had associated ocular
anomalies. In the present analyses of literature data 101
(54.30%) of the IP patients had associated ocular anom-
alies. In extensive meta-analyses 37.44% (289/772) of IP
patients with diagnosed eye anomalies were found [42].
The assumption that ocular anomalies increase the
chance of CNS anomalies in IP patients [30] was made
based on a very specific and relatively small sample. The
high number of accompanying ocular anomalies
reflected primarily common embryonic origin of eyes
and CNS. Besides ocular anomalies, dental and/or oral
anomalies were analyzed. They were present in 80
(69.56%) IP patients with CNS anomalies. There was a
higher correlation between CNS and dental and/or oral
anomalies than CNS and ocular anomalies. In an exten-
sive systematic review dental and/or oral anomalies were
diagnosed for 54.38% (279/513) of the investigated IP
patients [43]. A total of 41 IP patients had CNS, ocular,
and dental and/or oral anomalies simultaneously. Differ-
ent combinations of associated extracutaneous anomal-
ies in IP are likely to be the result of skewed X-
chromosome inactivation and due to the pleiotropic role
of IKBKG gene product [10,12,44].Because the epidermis, a key substrate of IP, and CNS
had same embryonic origin, it was supposed that IP
CNS changes are in accordance with their origin [4].
However, besides the fact that IKBKG gene mutations
were considered as the only cause of IP phenotype [4],
one must consider that other possibilities for their origin
may exist. This problem is related not only to CNS
anomalies associated with IP. A similar situation with
dental and oral anomalies was recently discussed in de-
tail [43]. Because IKBKG is involved in a complex NF-κB
signaling pathway that regulates the expression of hun-
dreds of genes [6], its mutation can produce different
disorders in organisms, and the entire spectrum of
anomalies seen in IP usually is attributed to IKBKG
mutations. Statistical data indicate that incidences of
typical CNS anomalies in IP were much higher than in
the general population. However, there are no absolute
facts that exclude the possibility that some other gene
mutations in IP patients besides IKBKG mutations exist
[44]. There are a great number of genes whose muta-
tions are responsible for different anomalies, including
some CNS anomalies found in IP: mental retardation,
seizure, and microcephaly. Besides involvement of
IKBKG gene mutation in mental retardation that is gen-
erally recognized [45], there are more than 290 other
genes involved in mental retardation [46]. Thus, it is
hypothetically possible that cutaneous manifestations in
IP originate from IKBKG mutation, whereas extracuta-
neous anomalies in IP patients originate from some gene
mutation other than IKBKG. According to this hypoth-
esis there is an option that combinations of mutations of
IKBKG and some other gene(s) are responsible for final
IP phenotype expression – skin changes and associated
extracutaneous anomalies. In the available literature
there are no facts to confirm or reject such a hypothesis.
So the possibility of the existence of a few different
mutations (including IKBKG) responsible for the
complete phenotypic characteristics of IP is still open.
According to Landy and Donnai’s IP diagnostic criteria
[3], skin lesions were classified as IP major criteria,
whereas dental, hair, nail, and retinal anomalies were
classified as IP minor criteria. Landy and Donnai [3]
registered a high percentage of CNS anomalies (<10%)
in their unpublished series of 111 IP patients, but omit-
ted CNS anomalies as IP minor criteria. Histological fea-
tures of affected skin and nipple anomalies as well as
oral anomalies, especially palate anomalies, were also
omitted so far as minor criteria [43,47]. To establish the
possibility to include CNS anomalies as IP minor cri-
teria, percentages of severe CNS anomalies and retinal
anomalies in IP were compared. In our meta-analysis of
eye anomalies in IP patients for the 1976–2010 period,
37.44% of IP patients with diagnosed eye anomalies were
found [42]. Retinal anomalies were present in 17.52% of
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is obvious that the total percentage of IP patients with
CNS (30.44%) and ocular anomalies (37.44%) [42] is
similar, as is the percentage of IP patients with vision-
threatening retinal (17.52%) [42] and severe CNS
(18.86%) anomalies. Taking into account that vision-
threatening retinal anomalies, already recognized as IP
minor criteria [3], were registered in a smaller percent-
age than severe CNS anomalies and the fact that CNS
anomalies represent the most important threat to the
normal life span of patients with IP [4], CNS anomalies
should be included as IP minor criteria.
Currently causative therapy for IP, including associated
CNS anomalies, does not exist. CNS anomalies are life
threatening and are the most severe consequences of IP.
Because CNS anomalies usually occur from the neonatal
through the early infantile period, fast referral of neo-
nates with IP to pediatric neurologists should be rou-
tinely considered.
Conclusion
CNS anomalies in IP patients pose a serious threat to
the normal life of an IP patient. The frequency of CNS
anomalies, similar to the frequency of retinal anomalies
in IP patients, concurrent with their severity, supports
their recognition in the list of IP minor criteria.
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